Literatura ACTA MEDICINAE 10/2019 Onkologie

Transkript

1 Literatura ACTA MEDICINAE 10/2019 Onkologie 3 Očekávání nového algoritmu léčby pokročilého karcinomu ledviny prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň 3 Použití molekulárněgenetických metod v klinické onkologii MUDr. Ľudmila Křížová prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha 3 Karcinom děložního hrdla, screening, význam HPV a možnosti testování As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě prof. MUDr. František Mateička, CSc. Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě 3 Nová éra v adjuvantní léčbě pokročilého melanomu MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 4 Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha 4 Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha 4 Současnost a výhledy v léčbě karcinomu prsu MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 4 Aktuální možnosti léčby karcinomu prsu MUDr. Zuzana Bielčiková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 5 Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu Studie MONALEESA-7 MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 5 Nemetastatický kastračně rezistentní karcinom prostaty MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 6 Lorlatinib zařazení do aktuální léčebné praxe MUDr. Juraj Kultan Klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci 6 Nový algoritmus léčby pokročilého NSCLC doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 7 Co nového v imunoterapii na WCLC 2019 MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha 7 Léčba kolorektálního karcinomu ve druhé linii Rozhovor Mgr. Dany Frantálové s MUDr. Radmilou Lemstrovou, doc. MUDr. Tomášem Büchlerem, Ph.D., MUDr. Petrou Klimčíkovou, MUDr. Jiřím Tomáškem, Ph.D., MUDr. Stanislavem Johnem a MUDr. Zdeňkem Linkem 7 Zkušenosti s bevacizumabem v první a druhé linii terapie pacientky s metastazujícím karcinomem rekta kazuistika MUDr. Michal Vočka Onkologická klinika, 1. LF UK a VFN, Praha 7 Tromboembolické komplikace u onkologických pacientů a jejich primární profylaxe prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLD a I. interní klinika VFN a 1. LF UK, Praha 8 Léčebné konopí MUDr. Marek Hakl, Ph.D. Centrum léčby bolesti, Medicinecare, s. r. o., Chirurgická klinika FN a LF MU, Brno 8 Možnosti léčby nádorové bolesti MUDr. Jan Lejčko Centrum pro léčbu bolesti Anesteziologicko-resuscitační kliniky FN Plzeň 8 Národní onkologické programy: klíč ke zlepšení onkologické péče Annual Cancer Media Summit

2 Literatura ACTA MEDICINAE 11/2019 Hematoonkologie 8 CAR-T lymfocyty v léčbě B-buněčných lymfomů MUDr. Pavel Otáhal, Ph.D. prof. MUDr. Marek Trněný, DrSc. I. interní klinika 1. LF a VFN, Praha 8 Immune checkpoint inhibitory v léčbě Hodgkinova lymfomu MUDr. Veronika Hanáčková doc. MUDr. Vít Procházka, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP, Olomouc 9 Konjugované monoklonální protilátky v léčbě lymfomů MUDr. Jan Kořen I. interní klinika klinika hematologie, 1. LF UK a VFN, Praha 9 Léčba nehodgkinských lymfomů monoklonálními protilátkami v roce 2019 MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN HK a LF UK v Hradci Králové 9 Bispecifické protilátky v léčbě akutní lymfoblastové leukemie a lymfomů MUDr. Kamila Polgárová prof. MUDr. Marek Trněný, CSc. Interní klinika klinika hematologie, 1. LF UK a VFN, Praha 10 Lymfom z plášťových buněk ve světle nových poznatků doc. MUDr. Pavel Klener, Ph.D. I. interní klinika hematologie, VFN a 1. LF UK, Praha 11 Relabující lymfom z plášťových buněk léčený úspěšně ibrutinibem kazuistika MUDr. Juraj Ďuraš prof. MUDr. Roman Hájek, CSc. Klinika hematoonkologie, FN Ostrava, Klinika hematoonkologie, LF Ostravské univerzity, Ostrava 11 Ibrutinib v léčbě refrakterního lymfomu z plášťových buněk kazuistika MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha 11 Použití ibrutinibu jako bridging k alogenní transplantaci krvetvorných buněk od haploidentického dárce a následné terapii reziduální nemoci po transplantaci u pacientky s vysoce nepříznivým průběhem lymfomu z plášťových buněk kazuistika MUDr. Veronika Válková, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální terapie UK, Praha 11 Cílená terapie chronické lymfocytární leukemie MUDr. Jakub Trizuljak prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, Lékařská fakulta a Fakultní nemocnice Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno 12 Venetoklax opakované použití u nemocné s prognosticky nepříznivou chronickou lymfocytární leukemií MUDr. Jana Zuchnická Klinika hematoonkologie Fakultní nemocnice Ostrava 12 Léčba esenciální trombocytemie anagrelidem MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 13 Buněčná terapie u akutních leukemií MUDr. Jan Vydra Ústav hematologie a krevní transfuze, Praha 13 Diagnostika a terapie sekundárních protilátkových imunodeficiencí u hematoonkologických pacientů z pohledu imunologa MUDr. Tomáš Milota Ústav imunologie 2. LF UK a FN v Motole, Praha

3 Očekávání nového algoritmu léčby pokročilého karcinomu ledviny prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň 1 Motzer, J. R. Tannir, N. M. McDermott, D. F.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med, 2018, 378, s Motzer, R. J. Tannir, N. M. Dermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. NEJM, Choueiri, T. K. Halabi, S. Sanford, B. L., et al.: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A CA- BOSUN Trial. J Clin Oncol, 2017, 35, s Rini, B. I. Plimack, E. R. Stus, V., et al.: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med, 2019, 380, s Motzer, J. R. Penkov, K. Haanen, J., et al.: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med, 2019, 380, s Motzer, R. J. Powles, T. Atkins, M. B., et al.: I Mmotion 151: A randomized phase iii study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mrcc). J Clin Oncol, 2018, 36, s Použití molekulárněgenetických metod v klinické onkologii MUDr. Ľudmila Křížová prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha 1 Petruželka, L.: Které nádory jsou skutečně vzácné? Onkol Rev, 2018, 4. 2 Sawyers, C.: Targeted cancer therapy. Nature, 2004, 432, s Petruželka, L.: Pohled na vývoj onkologie ve 3. tisíciletí. Klin Onkol, 2009, 22, s MacConaill, L. E. Garraway, L. A.: Clinical implications of the cancer genome. J J Clin Oncol, 2010, 28, s Jameson, J. L. Longo, D. L.: Precision medicine personalized, problematic, and promising. N Engl J Med, 2015, 372, s Hyman, D. M. Taylor, B. S. Baselga, J.: Implementing genome-driven oncology. Cell, 2017, 168, s Kurzrock, R. Giles, F. J.: Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle, 2015, 14, s National Laboratory of Enteric Pathogens, Bureau of Microbiology, Laboratory Centre for Disease Control: The polymerase chain reaction: An overview and development of diagnostic PCR protocols at the LCDC. Can J Infect Dis, 1991, 2, s Mullis, K. Faloona, F. Scharf, S., et al.: Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction Biotechnology, 1992, 24, s Tichopad, A., et al.: Standardized determination of real-time PCR efficiency from a single reaction set-up. Nucleic Acids Res, 2003, 31, s. e Banda, M.: Detection of mutant RAS subpopulations in colorectal cancer patients. E Bio Medicine, 2015, 2, s Jader, J. N. Sharif, S. B. Shakhinia, E.: Microsatellite instability in colorectal cancer. EXCLI J, 2018, 17, s Wolff, D. J.: Fluorescence in situ hybridization (FISH). In: The Principles of Clinical Cytogenetics, 2013, s Arbour, K. C. Riley, G. J.: Diagnosis and treatment of ALK positive NSCLC. Hematol Oncol Clin North Am, 2017, 31, s Gutierrez, C. Schiff, R.: HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med, 2011, 135, s Albarello, L. Pecciarini, L. Doglioni, C.: HER2 testing in gastric cancer. Adv Anat Pathol, 2011, 18, s Aitman, T. J.: Science, medicine, and the future: DNA microarrays in medical practice. BMJ, 2001, 323, s Bernard, P. S. Wittwer, C. T.: Real-time PCR technology for cancer diagnostics. Clin Chem, 2002, 48, s Chen, C. Y.: DNA polymerases drive DNA sequencing-by-synthesis technologies: Both past and present. Front Microbiol, 2014, 5, s Bennett, S. T. Barnes, C. Cox, A., et al.: Toward the 1,000 dollars human genome. Pharmacogenomics, 2005, 6, s Rizzo, J. M. Buck, M. J.: Key principles and clinical applications of next-generation DNA sequencing. Cancer Prev Res, 2012, 5, s Kamps, R. Brandão, R. Bosch, B., et al.: Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci, 2017, 18, s. pii: E Mark, J. R. Kucherov, V. Pintauro, M., et al.: What is the clinical utility of next generation sequencing (NGS) in advanced urologic malignancies? J Clin Oncol, 2019, 37, suppl., s Soukupová, J. Zemánková, P. Kleiblová, P., et al.: CZECANCA: CZEch CAncer panel for Clinical Application design and optimization of the targeted sequencing panel for the identification of cancer susceptibility in high-risk individuals from the Czech Republic. Klin Onkol, 2016, 29, suppl. 1, s. S46 S Neumann, M. H. D. Bender, S. Krahn, T., et al.: ctdna and CTCs in liquid biopsy current status and where we need to progress. Comput Struct Biotechnol J, 2018, 16, s Moorcraft, S. Y. Gonzalez, D. Walker, B. A.: Understanding next generation sequencing in oncology: A guide for oncologists. Crit Rev Oncol Hematol, 2015, 96, s Stricker, T. Catenacci, D. V. T. Seiwert, T. Y.: Molecular profiling of cancer the future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol, 2011, 38, s Subbiah, V. Kurzrock, R.: Universal genomic testing needed to win the war against cancer: Genomics IS the diagnosis. JAMA Oncol, 2016, 2, s Wheler, J. Lee, J. J. Kurzrock, R.: Unique molecular landscapes in cancer: Implications for individualized, curated drug combinations. Cancer Res, 2014, 74, s Slabý, O.: Technologie sekvenování nové generace: celogenomové, celoexomové a cílené hotspot sekvenování 2018, 31 Shyr, D. Liu, Q.: Next generation sequencing in cancer research and clinical application. Biol Proced Online, 2013, 15, s. 4. Karcinom děložního hrdla, screening, význam HPV a možnosti testování As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě prof. MUDr. František Mateička, CSc. Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě 1 Dušek, L. Mužík, J. Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit ]. Dostupný z WWW: svod.cz. Verze 7.0 [2007]. 2 De Sanjose, S. Quint, W. G. Alemany, L., et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11, s Tachezy, R. Mahelova, J. Salačova, M., et al.: Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One, 2011, 6, s Cibula, D. Petrželka, L., et al.: Onkogynekologie. Grada Publishing, Praha, 2009, s Dundr, P. Němejcová, K.: Prekancerózy a karcinomy děložního hrdla. Doporučený postup pro bioptické vyšetření. Společnost českých patologů, 6 McCluggage, W. G.: New developments in endocervical glandular lesions. Histopathology, 2013, 1, s Robová, H. Rob, L. Pluta, M., et al.: Guideline gynekologických zhoubných nádorů: Standard komplexní léčba časných stadií zhoubných nádorů děložního hrdla. Guideline C , 8 Sangrajrang, S. Laowahutanont, P. Wongsena, M., et al.: Human papillomavirus (HPV) DNA and mrna primary cervical cancer screening: Evaluation and triaging options for HPV-positive women. J Med Screen, Vink, F. J. Meijer, C. J. L. M. Clifford, G. M., et al.: FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. Int J Cancer, Nová éra v adjuvantní léčbě pokročilého melanomu MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 1 National Cancer Institute. Surveillance, epidemiology and end results (SEER). 12/ Leiter, U. Stadler, R. Mauch, C., et al.: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT). Lancet Oncol, 2016, 17, s Faries, M. B. Thompson, J. F. Cochran, A. J., et al.: Completion dissection or observation for sentinel node metastasis in melanoma. N Engl J Med, 2017, 376, s Ives, N. J. Suciu, S. Eggermont, A. M. M., et al.: International melanoma meta-analysis collaborative group (IMMCG). Adjuvant interferon alfa for the treatment of high risk melanoma: an individual patient data meta-analysis. Eur J Cancer, 2017, 82, s Eggermont, A. M. Chiarion-Sileni, V. Grob, J. J., et al.: Adjuvant ipilimumab versus placebo after complete resection of high risk stage III melanoma (EORTC 18071): a randomised, double blind, phase 3 trial. Lancet Oncol, 2015,16, s Eggermont, A. M. Chiarion-Sileni, V. Grob, J. J., et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med, 2016, 375, s Tarhini, A. A. Lee, J. S. Hodi, S., et al.: United states Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3or 10 mg/kg) versus high-dose interferon alfa 2b for resected high-risk melanoma. J Clin Oncol, 2019, 37, suppl., abstrakt Weber, J. Mandala, M. Del Vecchio, H. J., et al.: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med, 2017, 377, s Eggermont, A. M. M. Blank, C. U. Mandala, M., et al.: Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med, 2018, 378, s Long, G. V. Hauschild, A. Santinami, M., et al.: Adjuvant dabrafenib plus trametinib in stage III BRAF mutated melanoma. N Engl J Med, 2017, 377, s Hauschild, A. Dummer, R. Schadendorf, D., et al.: Longer follow-up confirms relaps free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600 mutant stage III melanoma. J Clin Oncol, 2018, 36, s Schadendorf, D. Hauschild, A. Santinami, M., et al.: Effect on health-related quality of life (HRQOL) of adjuvant treatment with dabrafenib plus trametinib in patients with resected stage III BRAF mutant melanoma. J Clin Oncol, 2018, 36, suppl., abstrakt 9590.

4 Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha 1 Haluska, F. G. Tsao, H. Wu, H., et al.: Genetic alteration in signaling pathways in melanoma. Clin Cancer Res, 2006, 12, s Menzies, A. M. Haydu, L. E. Visintin, L., et al.: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res, 2012, 18, s Long, G. V. Menzies, A. M. Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011, 29, s Chapman, P. B. Hauschild, A. Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, s Hauschild, A. Grob, J. J. Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380, s Robert, C. Karaszewska, B. Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015, 372, s Long, G. V. Stroyakovsky, D. K. Gogas, H., et al.: COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol, 2015, 33, suppl., abstrakt Robert, C. Grob, J. J. Stroyakovskiy, D., et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med, 2019, 381, s Long, G. V. Grob, J. J. Nathan, P., et al.: Factors predictive of response, diseas progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol, 2016, 17, s Hamid, O. Robert, C. Daud, A., et al.: 5-Year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. J Clin Oncol, 2018, 36, s. 9516, abstrakt. 11 Hodi, F. S. Kluger, H. Sznol, M., et al.: Durable, long-term survival in previously reated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Proc Am Assoc Cancer Res, 2016, 76, suppl., CT001, abstrakt. 12 Robert, C. Schachter, J. Long, G. V., et al.: 5-Year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Presented at the American Association for Cancer Research Annual Meeting, Atlanta, , abstrakt. 13 Prieto, P. A. Yang, J. C. Sherry, R. M., et al.: CTLA-4 blockade with ipilimumab: longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res, 2012, 18, s Maio, M. Grob, J. J. Aamdal, S., et al.: Five year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in aphase III trial. J Clin Oncol, 2015, 33, s Ugurel, S. Rohmel, J. Paolo, A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies update Eur J Cancer, 2017, 83, s Long, G. V. Weber, J. S. Infante, J. R., et al.: Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol, 2016, 34, s Weide, B. Martens, A. Hassel, J. C., et al.: Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res, 2016, 55, s Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha 1 Teicher, B. A. Doroshow, J. H.: The promise of antibody-drug conjugates. N Engl J Med, 2012, 367, s Verma, S. Miles, D. Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012, 367, s Současnost a výhledy v léčbě karcinomu prsu MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 1 Liedtke, C. Mazouni, C. Hess, K. R., e t al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26, s Osborne, C. R. Kannan, L. Xie, X. J., et al.: Neoadjuvant chemotherapy for basal-like breast cancer cohort: clinical and pathological outcomes. Breast Cancer Res and Treat, 2006, 100, s. S53. 3 Dent, R. Trudeau, M. Pritchard, K. I., et al.: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13, s Carey, L. A. Dees, E. C. Sawyer, L., et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007, 13, s Haffy, B. G. Yang, Q. Reiss, M., et al.: Locoregional relaps and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24, s Cortazar, P. Zhang, L. Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 2014, 384, s von Minckwitz, G. Untch, M. Blohmer, J. U., et al.: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012, 30, s Harbeck, N. Gluz, O.: Neoadjuvant therapy for triple negative and HER-2 positive early breast cancer. Breast, 2017, 34, s. S99 S Denkert, C. von Minckwitz, G. Darb-Esfahani, S., et al.: Tumour-infiltrating lymphocytes and prognosis in different subyteps of breast cancer: a pooled analysis of 3771 patients terated with neoadjuvant therapy. Lancet Oncol, 2018, 19, s Loi, S. Drubay, D. Adams, S., et al.: Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol, 2019, 37, s Schmid, P. Adams, S. Rugo, H. D., et al.: Atezolizumab and nab-pacliatxel in advanced triple-negative breast cancer. N Engl J Med, 2018, 29, 379, s Tolaney, S. M. Guo, H. Pernas, S., et al.: Seven-year follow-up of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2 positive breast cancer. J Clin Oncol, 2019, 37, s Guarneri, V. Dieci, M. V. Bisagni, G., et al.: De-escalated therapy for HR+/HER2+ breast cancer patients with KI67 response after 2 weeks letrozole: resulsts of the PerELISA neoadjuvant study. An Oncol, 2019, 30, s Rimawi, M. F. De Angelis, C. Contreras, A., et al.: Low PTEN levels and PIK3CA mutation predict resistence to enoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat, 2018, 167, s Pivot, X. Romieu, G. Debled, M., et al.: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. Lancet Oncol, 2013, 14, s Earl, H. M. Hiller, L. Vallier, A. L., et al.: 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSE- PHONE): 4-year disease-free survival results of a randomise phase 3 non-inferiority trial. Lancet, 2019, 393, s Conte, P. Frassoldati, A. Bisagni, G., et al.: Nine keks versus one aer adjutant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. An Oncol, 2018, 29, s Von Minckwitz, G. Huang, C. S. Mano, M. S., et al.: Trastuzumab emtansine for rezidual invasive HER2-positive breast cancer. N Engl J Med, 2019, 380, s McCart Reed, A. E. Kalita-deCroft, P. Kutasovic, J. R., et al.: Recent advances in breast cancer research impacting clinical diagnostic practice. J Pathol, 2019, 247, s Davies, C. Godwin, J. Gray, R., et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjutant tamoxifen: patient-level meta-analysis of randomized trials. Lancet, 2011, 378, s Schiavon, G. Smith, I. E.: Status of adjutant endocrine therapy for breast cancer. Breast Cancer Res, 2014, 16, s Turner, N. C. Ro, J. Andre, F., et al.: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med, 2015, 373, s Cristofanilli, M. Turner, C. N. Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive, HER2-negative metastatic breast cancer, that progressed on previous endocrine therapy (PALOMA-3): final analysis of multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s Turner, N. C. Slamon, D. J. Jungsil, R., et al.: Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med, 2018, 379, s Hortobagyi, G. N. Stemmer, S. M. Burris, H. A., et al.: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus letrozole alone in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol, 2018, 29, s Slamon, D. J. Neven, P. Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, 36, s Goetz, M. P. Toi, M. Campone, M., et al.: MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s Sledge, G. W. Jr. Toi, M. Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR1/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 25, s Andreé, F. Ciruelos, E. Rubovzsky, G., et al.: Alpelisib for PIK- 3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med, 2019, 380, s Aktuální možnosti léčby karcinomu prsu MUDr. Zuzana Bielčiková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 1 EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of women with early breast cancer in 26 randomised trial. Lancet, 2019, 393, s Masudan, N. Lee, S. J. Ohtani, S., et al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. NEJM, 2017, 376,

5 s Blum, J. L. Flynn, P. J. Yothers, G., et al.: Anthracyclines in early breast cancer: the ABC trials USOR , NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol, 2017, 35, s Ejlertsen, B. Tuxen, M. K. Jakobsen, E. H., et al.: Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TO- P2A-normal breast cancer: DBCG 07 READ, an open-label, phase iii, randomized trial. J Clin Oncol, 2017, 35, s Gluz, O. Nitz, U. Christgen, M., et al.: Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21- Gene Recurrence Score in high-risk HR+/HER2 early breast cancer (EBC) patients with 1 3 involved lymph nodes. The Breast, 2017, 32, s Gray, R., et al.: Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: A meta-analysis of 22,192 women in 11 randomized trials. SABCS, 2018, abstract G, s Prudence A. F. Pagani, O. Fleming, G. F., et al.: Tailoring adjuvant endocrine therapy for premenopausal breast cancer. NEJM, 2018, 379, s Sparano, J. A. Gray, R. J. Makower, D. F., et al.: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. NEJM, 2018, 379, s Cardoso, F. van t Veer, L. J. Bogaerts, J., et al.: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. NEJM, 2016, 375, s Gianni, L. Pienkowski, T. Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013, 24, s von Minckwitz, G. Procter, M. De Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. NEJM, 2017, 377, s Martin, M. Holmes, F. A. Ejlertsen, B., et al.: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 8, s Von Minckwitz, G. Huang, Ch. S. Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. NEJM, 2019, 380, s Tolaney, S. M. Barry, W. T. Guo H., et al.: Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol, 2017, 35, s Inno, A. Barni, S. Ghidini, A., et al.: One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 2019, 173, s Ruhstaller, T. Giobbie-Hurder, A. Colleoni, M., et al.: Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol, 2019, 2, s Cardoso, F. Costa, A. Senkus, E., et al.: 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, s Finn, R. S. Crown, J. P. Lang I., et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 2015, 16, s Finn, R. S. Martin, M. Rugo, H. S., et al.: Palbociclib and letrozole in advanced breast cancer. NEJM, 2016, 375, s Hortobagyi, G. N. Stemmer, S. M. Burris, H. A., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. NEJM, 2016, 375, s Goetz, M. P. Toi, M. Campone, M., et. al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s Slamon, D. J. Neven, P. Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, 36, s Tripathy, D. Im, S. A. Colleoni, M., et al.: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomized phase 3 trial. Lancet Oncol, 2018, 19, s Im, S. A. Lu, Y. S. Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. NEJM, 2019, 381, s Neven, P. Rugo, H. S. Tolaney, S. M., et al.: Abemaciclib for pre/ perimenopausal women with HR+, HER2 advanced breast cancer. J Clin Oncol, 2018, 36, abstrakt Loibl, S. Rurner, N. C. Ro, J., et al.: Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist, 2017, 22, s Robertson, J. F. Bondarenko, I. M. Trishina, E., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Oncol, 2016, 388, s Metha, R. S. Barlow, W. E. Albain, K. S., et al.: Combination anastrozole and fulvestrant in metastatic breast cancer. NEJM, 2012, 367, s Ellis, M. J. Llombart-Cussak, A. Feltl, D., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST Study. J Clin Oncol, 2015, 32, s Baselga, J. Campone, M. Piccart, M., et al.: Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. NEJM, 2012, 366, s Andre, F. Ciruelos, E. M. Rubovszky, G., et al.: LBA3_PR: Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Ann Oncol, 2018, abstr. LBA3. 33 Sledge, G. W. Toi, M. Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 35, s Cristofanelli, M. Turner, N. C. Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s Dickler, M. Tolaney, S. M. Rugo, H. S., et al.: MONARCH-1: results from a phase 2 study of abemaciclib, CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2 breast cancer, after chemotherapy for metastatic disease. J Clin Oncol, 2016, 34, abstrakt Barroso Sousa, R. Shapiro, G. I. Tolaney, S. M.: Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care (Basel), 2016, 11, s Varella, L. Abraham, J. Kruse, M., et al.: Revisiting the role of bevacizumab in the treatment of breast cancer. Semin Oncol, 2017, 44, s Schmid, P. Adams, S. Rugo, H. S., et al.: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-p) vs placebo + nab-p in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mtnbc). Ann Oncol, 2018, 29, abstrakt LBA1_PR. 39 Loi, S. Drubay, D. Adams, S., et al.: Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol, 2019, 37, s Robson, M. E. Im, S. Senkus, E., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. NEJM, 2017, 377, s Robson, M. E. Tung, N. Conte, P., et al.: OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol, 2019, 30, s Slamon, D. J. Leyland-Jones, B. Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM, 2001, 344, s Gelmon, K. Boyle, F. Kaufman, B., et al.: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF J Clin Oncol, 2012, 30, abstrakt LBA Hurvitz, S. A. Andre, F. Jiang, Z., et al.: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol, 2015, 6, s Baselga, J. Cortez, J. Kim S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEJM, 2012, 366, s Swain, S. M. Baselga, J. Kim, S. B., et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. NEJM, 2015, 372, s Romond, E. H. Perey, E. A. Brzant, J., et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM, 2005, 353, s Verma, S. Miles, D. Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. NEJM, 2012, 367, s Andre, F. O Regan, R. Ozguroglu, M., et al.: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, doubleblind. Lancet Oncol, 2014, 15, s Harbeck, N. Huang, C. H. S. Hurvitz, S., et al.: Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol, 2016, 17, s Krop, I. E. Kim, S. B. Gonzáles-Martín, A., et al.: Trastuzumab emtansine versus treatment of physician s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol, 2014, 15, s Blackwell, K. L. Burstein, H. J. Storniolo, A. M., et al.: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 2010, 28, s Sella, T.: 8 th Annual Fellows Forum in Breast Oncology 2019, přednáška. 54 Marra, A.: 8 th Annual Fellows Forum in Breast Oncology 2019, přednáška. Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu Studie MONALEESA-7 MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 1 Caldon, C. E. Daly, R. J. Sutherland, R. L. Musgrove, E. A.: Cell cycle control in breast cancer cells. J Cell Biochem, 2006, 97, s Koboldt, D. C. Fulton, R. S. McLellan, M. D., et al.: Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490, s Zardavas, D. Baselga, J. Piccart, M.: Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol, 2013, 10, s Im, S. A. Lu, Y. S. Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med, 2019, doi: /NEJMoa , epub před tiskem. Nemetastatický kastračně rezistentní karcinom prostaty MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 1 Freedland, S. J. Richhariya, A. Wang, H., et al.: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology, 2012, 80, s Esther, J. Maughan, B. J. Anderson, N., et al.: Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options in Oncol, 2019, 20, s Smith, M. R. Saad, F. Chowdhury, S., et al.: Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med, 2018, 378, s Hussain, M. Fizazi, K. Saad, F., et al.: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med, 2018, 378, s Fizazi, K. Shore, N. Tammela, T. L., et al.: Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med, 2019, DOI: /NEJMoa

6 6 Beaver, J. A. Kluetz, P. G. Pazdur, R.: Metastasis-free survival: a new end point in prostate cancer trials. N Engl J Med, 2018, 378, s Afshar, M. Evison, F. James, N. D., et al.: Shifting paradigms in the estimation of survival for castration resistant prostate cancer: a tertiary academic center experience. Urol Oncol, 2015, 33, s. 338.e Smith, M. R. M. M. Nair, S. Lawson, J., et al.: Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmcrpc). J Clin Oncol, 2018, 36, abstrakt Lorlatinib zařazení do aktuální léčebné praxe MUDr. Juraj Kultan Klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci 1 Robinson, D. R. Wu, Y. M. Lin, S. F.: The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19, s Hubbard, S. R. Miller, W. T.: Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol, 2007, 19, s Sanz-Ezquerro, J. J. Münsterberg, A. E. Stricker, S.: Editorial: signaling pathways in embryonic development. Front Cell Dev Biol, 2017, 5, s Bayliss, R. Choi, J. Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci, 2016, 73, s Mathas, S. Kreher, S. Meaburn, K. J., et al.: Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A, 2009, 106, s Du, X. Shao, Y. Qin, H. F., et al.: ALK-rearrangement in non-smallcell lung cancer (NSCLC). Thorac Cancer, 2018, 9, s Morris, S. W., et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin s lymphoma. Science, 1994, 263, s Soda, M. Choi, Y. L. Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, s Hallberg, B. Palmer, R. H.: The role of the ALK receptor in cancer biology. An Oncol, 2016, 27, suppl. 3, s. iii4 iii Guan, J. Umapathy, G. Yamazaki, Y., et al.: FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife, 2015, 4, e Bayliss, R. Choi, J. Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci, 2016, 73, s Lin, J. J. Riely, G. J. Shaw, A. T., et al.: Precision medicine takes on drug resistance. Cancer Discov, 2017, 7, s Chiarle, R. Voena, C. Ambrogio, C., et al.: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 2008, 8, s Sehgal, K. Patell, R. Rangachari, D., et al.: Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res, 2018, 7, suppl. 7, s. S779 S Shaw, A. T. Ou, S. H. Bang, Y. J., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371, s Hofman, P.: ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers (Basel), 2017, 9, s Le, T. Gerber, D. E.: ALK alterations and inhibition in lung cancer. Semin Cancer Biol, 2017, 42, s Shaw, A. T. Yeap, B. Y. Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27, s Yang, P. Kulig, K. Boland, J. M., et al.: Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol, 2012, 7, s Barlesi, F. Mazieres, J. Merlio, J. P., et al.: Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, 2016, 387, s Bergethon, K. Shaw, A. T. Ou, S. H., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30, s Warth, A. Muley, T. Dienemann, H., et al.: ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology, 2014, 65, s Huber, K. V. Salah, E. Radic, B., et al.: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 2014, 508, s Kazandjian, D. Blumenthal, G. M. Chen, H. Y., et al.: FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist, 2014, 19, s. e5 e Dostupné z: vyhlednáno Shaw, A. T. Dong-Wan, K. Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013, 368, s Solomon, B. J. Mok, T. Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Eng J Med, 2014, 371, s Sharma, G. G. Mota, I. Mologni, L., et al.: Tumor resistance against ALK targeted therapy-where it comes from and where it goes. Cancers (Basel), 2018, 10, s Rothenstein, J. M. Chooback, N.: ALK inhibitors, resistance development, clinical trials. Curr Oncol, , suppl. 1, s. S59 S Sullivan, I. Planchard, D.: ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol, 2016, 8, s Shaw, A. T. Solomon, B. Lilenbaum, R. C., et al.: Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer, dostupné z: vyhledáno Gainor, J. F. Dardaei, L. Yoda, S., et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov, 2016, 6, s Shaw, A. T. Friboulet, L. Leshchiner, I., et al.: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med, 2016, 374, s Le, T. Gerber, D. E.: ALK alterations and inhibition in lung cancer. Semin Cancer Biol, 2017, 42, s Shaw, A. T. Felip, E. Bauer, T. M., et al.: Lorlatinib in non-smallcell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol, 2017, 18, s Solomon, B. J. Besse, B. Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 2018, 19, s Dostupné z: vyhledáno Desai, A. Sriwastava, S. Gadgeel, S. M., et al.: New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a nowel anti-cancer agent. J Neurol Sci, 2018, 392, s Chabrol, A. Mayenga, M. Hamid, A. M., et al.: Lorlatinib Induced pulmonary arterial hypertension. Lung Cancer, 2018, 120, s Pacheco, J. P. Gao, D. Smith, D., et al.: Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol, 2019, 14, s Nový algoritmus léčby pokročilého NSCLC doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 1 ÚZIS ČR, NOR ČR 2015, Novotvary 2015, Cancer Incidence 2015 in the Czech Republic. 2 Curran, W. J. Jr. Paulus, R. Langer, C. J., et al.: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG J Natl Cancer Inst, 2011, 103, s Aupérin, A. LePéchoux, C. Rolland, E., et al.: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28, s Antonia, S. J. Villegas, A. Daniel, D., et al.; PACIFIC Investigators: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med, 2018, 379, s Mok, T. S. Wu, Y. L. Thongprasert, S., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361, s Lee, C. K. Davies, L. Wu, Y. L., et al.: Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overal survival. J Natl Cancer Inst, 2017, Yang, J. C. Wu, Y. L. Schuler, M., et al.: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 2015, 16, s Soria, J.-C. Ohe, Y. Vansteenkiste, J., et al.; FLAURA Investigators: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378, s Wu, Y. L. Cheng, Y. Zhou, X., et al.: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cance (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18, s Kato, T. Seto, T. Nishio, M., et al.: Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf, 2018, 41, s Mok, T. S. Wu, Y. I. Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376, s Solomon, B. J. Mok, T. Kim, D. W., et al.; PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 2014, 371, s Shaw, A. T. Kim, T. M. Crinò, L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2017, 18, s Camidge, D. R. Dziadziuszko, R. Peters, S., et al.: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol, 2019, pii: S , s Kim, D. W. Tiseo, M. Ahn, M. J., et al.: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-smallcell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol, 2017, 35, s Solomon, B. J. Besse, B. Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 2018, 19, s , doi: / S (18) , Epub , erratum in: Lancet Oncol, 2019, 20, e Planchard, D. Smit, E. F. Groen, H. J. M., et al.: Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 2017, 18, s Joshi, A. Pande, N. Noronha, V., et al.: ROS1 mutation non-small cell lung cancer access to optimal treatment and outcomes. E Cancer Medical Science, 2019, 13, s Reck, M. Rodríguez-Abreu, D. Robinson, A. G., et al.; KEY- NOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375, s Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.; KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic nonsmall-cell lung cancer. N Engl J Med, 2018, 378, s Reck, M. von Pawel, J. Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small-cell lung cancer: AVAiL. J Clin Oncol, 2009, 28, s Sculier, J. Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non small cell lung cancer. Eur Respir J, 2009, 33, s Scagliotti, G. V. Parikh, P. Pavel, J., et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patiens with advanced-stage non small-cell lung cancer. J Clin Oncol, 2008, 26, s Lee, D. H.: Treatments for EGFR-mutant non-small-cell lung cancer (NSCLC): The road to a success, paved with failures. Pharmacol Ther, 2017, 174, s Gadgeel, S. Peters, S. Mok, T., et al.: Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) nonsmall-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol, 2018, 29, s Thatcher, N. Hirsch, F. R. Luft, A. V., et al.; SQUIRE Investigators: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol, 2015, 16, s Gerber, D. E. Schiller, J. H.: Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin